<DOC>
	<DOCNO>NCT00783965</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , tazarotene , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This randomized phase II trial compare two different schedule topical tazarotene topical placebo see well work treat patient basal cell skin cancer basal cell nevus syndrome chest .</brief_summary>
	<brief_title>Topical Tazarotene Treating Patients With Basal Cell Skin Cancer Basal Cell Nevus Syndrome Chest Back</brief_title>
	<detailed_description>OBJECTIVES : Primary - To expand refine chemopreventive strategy individual basal cell nevus syndrome ( BCNS ) chest back , high risk development basal cell carcinoma ( BCCs ) . - To determine whether tazarotene 0.1 % cream apply chest two year reduce number basal cell carcinoma ( BCCs ) observe , compare number expect , base change BCC number observe month 0-12 . Secondary - To compare difference total BCC burden ( measure total lesion surface area ) chest back various time point aggregate interval interest . - To determine whether detectable wash-in wash-out period tazarotene effect . - Explore use random effect model longitudinal analysis total lesion time . OUTLINE : This multicenter study . Patients randomize 1 2 arm . - Arm I : Patients apply 0.1 % tazarotene cream month 0-12 vehicle ( placebo ) month 13-36 daily chest absence disease progression unacceptable toxicity . - Arm II : Patients apply vehicle ( placebo ) month 0-12 0.1 % tazarotene cream month 13-36 daily chest absence disease progression unacceptable toxicity . Treated chest untreated back evaluated 3 month interval 36 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Basal Cell Nevus Syndrome</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>List 1 . Study subject must least one basal cell carcinoma â‰¥ 3mm diameter ( target lesion ) area skin except face , chest , back ( impinge vital site ) diagnose clinically Study Investigator baseline visit . 2 . Study subject must meet diagnostic criterion basal cell nevus syndrome include major criterion # 1 plus one additional major criterion two minor criterion outline Table I . A first degree relative would satisfy BCNS diagnostic criterion two major criterion single major plus two minor criterion . Table I. BCNS Diagnostic Criteria Major criterion 1 . More 2 BCCs one age 20 year 2 . Odontogenic keratocysts jaw proven histology 3 . Three palmar and/or plantar pit 4 . Bilamellar calcification falx cerebri ( less 20 year old ) 5 . Fused , bifid , markedly splay rib . 6 . First degree relative basal cell nevus syndrome ( BCNS ) 7 . PTCH1 gene mutation normal tissue* Minor criterion 1 . Macrocephaly determine adjustment height 2 . Congenital malformation : cleft lip palate , frontal bossing , `` coarse face . '' 3 . Skeletal abnormality : Sprengel deformity , mark pectus deformity 4 . Radiological abnormality : bridging sella turcica , vertebral anomaly hemivertebrae , fusion elongation vertebral body . 5 . Ovarian fibroma 6 . Medulloblastoma 3.The subject 1875 year age , inclusive . 4 . If subject female childbearing potential ( woman consider childbearing potential least 2 year postmenopausal and/or surgically sterile ) , : i. use adequate contraception ( abstinence , IUD , birth control pill , spermicidal gel diaphragm condom ) since last menses use adequate contraception study , ii . lactating , iii . document one negative serum pregnancy test within 14 day prior study entry . 5 . The subject willing abstain application nonstudy topical medication skin face duration study , include prescription counter preparation . 6 . The subject willing target BCCs treat PSCP unless BCCs document Study Investigators , preferably two separate visit , except PSCP believe delay treatment potentially might compromise health subject . List 1 . The subject use topical systemic therapy might interfere evaluation study medication study . 2 . The subject history hypersensitivity ingredient study medication formulation . 3 . The subject unable return followup test . 4 . The subject uncontrolled systemic disease , include know HIV positive patient . 5 . The subject history skin condition significant illness would interfere evaluation study medication . 6 . Any condition situation Investigator 's opinion may put subject significant risk , could confound study result , could interfere significantly subject 's participation study . 7 . The subject history invasive cancer within past five year exclude nonmelanoma skin cancer , Stage I cervical cancer , CLL Stage 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>nevoid basal cell carcinoma syndrome</keyword>
	<keyword>basal cell carcinoma skin</keyword>
</DOC>